Poznámky k epizodě
True-Sciences.com Use Code Pep20 for 20% off.
A careful look at CJC-1295: the growth-hormone pathway, the distinction between DAC and no-DAC naming, what small human studies measured, the terminated Phase 2 trial, current FDA compounding information, the unproven CJC-1295/ipamorelin combination claims, and WADA's 2026 rules. The evidence supports a hormone effect for the long-acting DAC-modified compound; it does not establish the benefits often marketed for consumer products. Educational content only; not medical advice. Snapshot checked October 19, 2026.
Web: c8cc7b72-7bf7-4a91-b244-e1418d70a491.libsyn.com

